<!DOCTYPE html>
<html lang="fa">
 <meta content="text/html;charset=utf-8" http-equiv="content-type"/>
 <head>
  <title>
   Unipolar depression in adults: Treatment with anxiolytics
  </title>
  <link href="d/css/1.css" rel="stylesheet"/>
 </head>
 <body>
  <!-- Start Main Menu Area -->
  <br/>
  <br/>
  <br/>
  <br/>
  <div class="container">
   <div class="row">
   </div>
  </div>
  <section class="teacher-area ptb-10">
   <div class="container">
   </div>
   <section class="course-details-area ptb-60">
    <div class="container">
     <div class="uptodate2" style="padding:50px 0px 50px 0px;direction: ltr;text-align: left;">
      <h1 style="text-align:center">
       Unipolar depression in adults: Treatment with anxiolytics
      </h1>
      <div class="utdArticleSection utdStyle" id="topicContent">
       <div id="topicTitle">
        Unipolar depression in adults: Treatment with anxiolytics
       </div>
       <div class="authorSectionElem">
        <div class="authorsElementsLeft">
         <dl id="topicContributors">
          <dt>
           <span>
           </span>
           Author:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Andrew Goddard, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Section Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            Peter P Roy-Byrne, MD
           </a>
          </dd>
          <dt>
           <span>
           </span>
           Deputy Editor:
          </dt>
          <dd>
           <a class="contributor contributor_credentials" rel="noopener noreferrer" target="_blank">
            David Solomon, MD
           </a>
          </dd>
         </dl>
        </div>
        <div class="authorsElementsRight">
         <div id="literatureReviewDate">
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             Literature review current through:
            </span>
            Jan 2024.
           </bdi>
          </div>
          <div class="litReviewSingleLine">
           <bdi>
            <span class="emphasis">
             This topic last updated:
            </span>
            Apr 15, 2023.
           </bdi>
          </div>
         </div>
        </div>
       </div>
       <div id="topicWhatsNewContainer">
       </div>
       <div id="topicText">
        <p class="headingAnchor" id="H30535202">
         <span class="h1">
          INTRODUCTION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unipolar major depression that includes high levels of anxiety symptoms (often called anxious depression) is common [
         <a href="#rid1">
          1,2
         </a>
         ]. In a study of 2876 patients with major depression, high levels of anxiety were present in more than 50 percent [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p>
         Treatment of anxious depression frequently includes anxiolytic drugs [
         <a href="#rid4">
          4,5
         </a>
         ]. In addition, insomnia that is part of the depressive syndrome often responds to anxiolytic (hypnotic) therapy [
         <a href="#rid6">
          6
         </a>
         ].
        </p>
        <p>
         This topic reviews the use of anxiolytics to treat unipolar major depression, including their indications, contraindications, administration, and efficacy. Choosing a medication regimen for the initial treatment of depression and for treatment resistant depression is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1725.html" rel="external">
          "Unipolar major depression in adults: Choosing initial treatment"
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H1664453">
         <span class="h1">
          ANXIOUS DEPRESSION
         </span>
         <span class="headingEndMark">
          —
         </span>
         Unipolar major depression that includes high levels of anxiety symptoms is often called “anxious depression” [
         <a href="#rid7">
          7
         </a>
         ]. The clinical features and diagnosis of anxious depression are discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/91774.html" rel="external">
          "Unipolar depression in adults: Clinical features", section on 'Anxious'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">
          "Unipolar depression in adults: Assessment and diagnosis", section on 'Depressive episode subtypes (specifiers)'
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30535209">
         <span class="h1">
          INDICATIONS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Indications for augmenting antidepressants with anxiolytics to treat unipolar major depression include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Symptoms of anxiety, such as ruminative thoughts, worrying, health anxieties, excessive fears, and panic attacks. Major depression that includes high levels of anxiety is often referred to as “anxious depression,” and severe anxiety can increase the risk of suicide attempts [
         <a href="#rid8">
          8
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Moderate to severe insomnia [
         <a href="#rid9">
          9
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Psychomotor agitation (eg, pacing and handwringing) [
         <a href="#rid10">
          10
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Excessive activation (jitteriness) induced by antidepressants such as selective serotonin reuptake inhibitors (SSRIs) and tricyclics [
         <a href="#rid11">
          11
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         The need to accelerate improvement in patients with moderate to severe depression [
         <a href="#rid12">
          12
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Treatment resistant depression (eg, nonresponse to at least two separate, adequate antidepressant trials). (See
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression"
         </a>
         .)
        </p>
        <p>
        </p>
        <p>
         The short term goals of co-administering anxiolytics with antidepressants are rapid anxiolysis, control of insomnia and agitation, and limiting antidepressant side effects. The longer term aim is remission of the depressive syndrome.
        </p>
        <p class="headingAnchor" id="H87788652">
         <span class="h2">
          Contraindications
         </span>
         <span class="headingEndMark">
          —
         </span>
         In treating depressive syndromes, the following comorbidities are contraindications to augmenting antidepressants with anxiolytics, especially benzodiazepines:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Chronic posttraumatic stress disorder (PTSD)
         </strong>
         – There is no compelling evidence that benzodiazepines are effective for the core PTSD symptoms in this clinical context [
         <a href="#rid13">
          13
         </a>
         ]. In some patients, there is a risk of worsening PTSD symptoms such as hyperarousal and irritability.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe antisocial or borderline personality disorder
         </strong>
         – Long term administration of benzodiazepines is likely to worsen impulsivity in these patients [
         <a href="#rid14">
          14
         </a>
         ]. In addition, patients with these severe personality disorders are more prone to benzodiazepine dependence, and are more likely to engage in drug diversion.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Moderate to severe substance use disorders antedating onset of the depressive syndrome
         </strong>
         – Patients whose history suggests a long-standing primary substance disorder are at higher risk for becoming dependent upon benzodiazepines [
         <a href="#rid15">
          15
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild cognitive impairment or dementia
         </strong>
         – Most anxiolytics should be used with caution in dementia patients. However, we avoid long-term administration of benzodiazepines in this context, due to their sedative and amnestic properties, and risk of exacerbating cognitive impairments [
         <a href="#rid16">
          16
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          General medical conditions such as severe myopathic disorders (eg, myasthenia gravis) and chronic respiratory diseases (eg, severe chronic obstructive pulmonary disease)
         </strong>
         – The muscle relaxant properties of anxiolytics, especially benzodiazepines, are likely to exacerbate these diseases [
         <a href="#rid17">
          17,18
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H90524849">
         <span class="h1">
          GENERAL PRINCIPLES
         </span>
        </p>
        <p class="headingAnchor" id="H10011920">
         <span class="h2">
          Patient assessment
         </span>
         <span class="headingEndMark">
          —
         </span>
         The initial clinical evaluation of patients with a possible diagnosis of unipolar major depression with anxiety includes a psychiatric history and mental status examination, with emphasis upon depressive and anxiety symptoms [
         <a href="#rid19">
          19-22
         </a>
         ]. The clinician should also obtain a general medical history, physical examination, and laboratory tests that are guided by the history and examination. Unipolar major depression is generally diagnosed according to the American Psychiatric Association's Diagnostic and Statistical Manual, Fifth Edition (DSM-5)  (
         <a class="graphic graphic_table graphicRef89994" href="/z/d/graphic/89994.html" rel="external">
          table 1
         </a>
         ) [
         <a href="#rid23">
          23
         </a>
         ].
        </p>
        <p>
         Assessment of major depression can be facilitated by using the Patient Health Questionnaire - Nine Item (PHQ-9)  (
         <a class="graphic graphic_table graphicRef59307" href="/z/d/graphic/59307.html" rel="external">
          table 2
         </a>
         ), which is a nine-item self-report instrument that screens for episodes of major depression, has good psychometric properties, is in the public domain, and can be filled out by patients prior to the appointment [
         <a href="#rid24">
          24
         </a>
         ]. An alternative is the two item Patient Health Questionnaire, which screens for depression but does not provide a diagnosis; patients who screen positive must be interviewed by the clinician to establish the diagnosis of major depression [
         <a href="#rid25">
          25
         </a>
         ]. Additional information about diagnosing major depression and the PHQ-9 is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/1721.html" rel="external">
          "Unipolar depression in adults: Assessment and diagnosis", section on 'Unipolar major depression'
         </a>
         and
         <a class="medical medical_review" href="/z/d/html/14860.html" rel="external">
          "Using scales to monitor symptoms and treat depression (measurement based care)", section on 'Patient Health Questionnaire - Nine Item'
         </a>
         .)
        </p>
        <p>
         The initial assessment of anxiety symptoms (eg, excessive fears and worrying) can be facilitated with the seven item self-report scale for generalized anxiety disorder (GAD-7)  (
         <a class="graphic graphic_table graphicRef77755" href="/z/d/graphic/77755.html" rel="external">
          table 3
         </a>
         ), which is in the public domain [
         <a href="#rid26">
          26
         </a>
         ]. An alternative self-report questionnaire is the Beck Anxiety Inventory, which consists of 21 items and focuses upon somatic symptoms, but is copyrighted and must be purchased [
         <a href="#rid27">
          27,28
         </a>
         ]. In addition, the 14 item Hamilton Anxiety Rating Scale assesses global anxiety, including psychic (cognitive) and somatic symptoms, and is in the public domain; however, this is a clinician administered instrument [
         <a href="#rid29">
          29,30
         </a>
         ].
        </p>
        <p>
         Following the initial evaluation, the effectiveness of treatment can be monitored with the PHQ-9 and GAD-7. A reasonable alternative is to use self-report visual analog scales; as an example, one Likert response item for level of depression and another for level of anxiety, each ranging from 0 (none) to 10 (extreme).
        </p>
        <p class="headingAnchor" id="H5087207">
         <span class="h2">
          When to start the anxiolytic
         </span>
         <span class="headingEndMark">
          —
         </span>
         In treating unipolar major depression with an adjunctive anxiolytic, the point at which the drug is added depends upon the severity of the depressive syndrome:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Severe
         </strong>
         – For severe depression that includes anxiety and/or insomnia, we typically start the anxiolytic at the same time as the antidepressant or soon thereafter (eg, within one to two weeks).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Mild to moderate
         </strong>
         – For mild to moderate depression, we typically use a stepped care approach and start the anxiolytic later [
         <a href="#rid31">
          31
         </a>
         ]. The antidepressant is titrated up and then administered for a sufficient period (eg, four to eight weeks) to evaluate its efficacy as monotherapy. If anxiety and/or insomnia persist, we then add the anxiolytic.
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H10011853">
         <span class="h2">
          Duration of treatment
         </span>
         <span class="headingEndMark">
          —
         </span>
         Based upon randomized trials, we suggest that clinicians co-administer the anxiolytic and the antidepressant for four to six weeks [
         <a href="#rid4">
          4,12,32,33
         </a>
         ]. There is little evidence that longer treatment is beneficial. When treatment with the anxiolytic is completed, the drug is tapered for two to four weeks prior to discontinuation. Information about discontinuing benzodiazepines is discussed elsewhere in this topic (see
         <a class="local">
          'Benzodiazepines'
         </a>
         below).
        </p>
        <p class="headingAnchor" id="H10011913">
         <span class="h1">
          SPECIFIC DRUGS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Specific anxiolytic drugs include:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Benzodiazepines (eg,
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         and
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Nonbenzodiazepine hypnotics (eg,
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          zolpidem
         </a>
         and
         <a class="drug drug_general" data-topicid="8830" href="/z/d/drug information/8830.html" rel="external">
          eszopiclone
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Second-generation antipsychotics (eg,
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         and
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         )
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9774" href="/z/d/drug information/9774.html" rel="external">
          Pindolol
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">
          Buspirone
         </a>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Other agents (
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         and
         <a class="drug drug_general" data-topicid="9865" href="/z/d/drug information/9865.html" rel="external">
          riluzole
         </a>
         )
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H30535216">
         <span class="h2">
          Benzodiazepines
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with unipolar major depression, adding a benzodiazepine to an antidepressant can improve anxiety, insomnia and other symptoms of depression, and treatment adherence [
         <a href="#rid12">
          12,34-36
         </a>
         ]. A meta-analysis of 10 randomized trials that compared adjunctive benzodiazepines with placebo in 731 depressed patients who received antidepressants found that at four weeks [
         <a href="#rid4">
          4
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Severity of depression was less with a benzodiazepine plus an antidepressant than antidepressant monotherapy; heterogeneity across trials was moderate to large. (The difference in depressive symptoms between the two treatment groups was greatest after one week and not demonstrable beyond six to eight weeks.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Response (improvement from baseline on the depression rating scale ≥50 percent) occurred in more patients who received combination treatment than monotherapy (50 versus 38 percent); heterogeneity was small to moderate.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Discontinuation of treatment due to adverse effects occurred in fewer patients who received adjunctive benzodiazepines than placebo (7 versus 13 percent); there was little to no heterogeneity across studies.
        </p>
        <p>
        </p>
        <p>
         However, the benefits of adding a benzodiazepine must be balanced against potential harms that include tolerance (diminished effect over time), physiologic dependence, sedation, amnestic effects, impaired psychomotor speed, and increased accidents [
         <a href="#rid4">
          4,16,37
         </a>
         ]. Benzodiazepines should be used cautiously or avoided in patients with a history of alcohol or substance abuse, or a history of problematic adherence to antidepressants; both groups may want to stop the antidepressant and continue only the benzodiazepine due to the benzodiazepine’s more rapid clinical effect.
        </p>
        <p>
         If a benzodiazepine is indicated during treatment of unipolar major depression with an antidepressant, we generally start
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         at a dose of 0.5 mg at bedtime and titrate up over one to two weeks to a maximum dose of 2 mg per day, given at bedtime or divided in two daily doses. Although each of the benzodiazepines can be prescribed adjunctively with an antidepressant to treat unipolar depression, we prefer high potency, intermediate half-life agents (eg, clonazepam or
         <a class="drug drug_general" data-topicid="9573" href="/z/d/drug information/9573.html" rel="external">
          lorazepam
         </a>
         ). Compared with low potency, longer half-life drugs (eg,
         <a class="drug drug_general" data-topicid="9243" href="/z/d/drug information/9243.html" rel="external">
          chlordiazepoxide
         </a>
         or
         <a class="drug drug_general" data-topicid="9345" href="/z/d/drug information/9345.html" rel="external">
          diazepam
         </a>
         ), high potency, intermediate half-life agents generally have simpler metabolisms with fewer active metabolites, and may thus have a lower risk of sedation and psychomotor problems such as falls [
         <a href="#rid38">
          38
         </a>
         ]. In addition, clonazepam has been frequently studied for augmentation of antidepressants [
         <a href="#rid12">
          12,34,35
         </a>
         ]. Information about the pharmacology of benzodiazepines, including doses, comparative potency, metabolism, and half-life is presented in the table  (
         <a class="graphic graphic_table graphicRef65653" href="/z/d/graphic/65653.html" rel="external">
          table 4
         </a>
         ).
        </p>
        <p>
         Based upon our clinical experience, patients should avoid using benzodiazepines on an as needed basis (PRN administration) because this approach is often not effective; fluctuating serum concentrations, especially with short acting drugs (eg,
         <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">
          alprazolam
         </a>
         ), can increase the risk of minor withdrawal reactions and reinforce psychological dependence. In addition, as needed dosing may interfere with cognitive-behavioral therapy (CBT), by promoting rescue medication as a coping strategy that competes with the coping skills taught in CBT [
         <a href="#rid39">
          39
         </a>
         ].
        </p>
        <p>
         Benzodiazepines should be tapered over two to four weeks prior to discontinuation; tapering over a period less than two weeks may lead to rebound symptoms of depression and anxiety [
         <a href="#rid34">
          34,40
         </a>
         ], and abrupt discontinuation can cause seizures. For patients who have been on a benzodiazepine for more than six months, we typically decrease the total daily dose by 10 percent every week until discontinuation. The benzodiazepine withdrawal syndrome is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/141183.html" rel="external">
          "Benzodiazepine withdrawal"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H10010939">
         <span class="h3">
          Alprazolam monotherapy
         </span>
         <span class="headingEndMark">
          —
         </span>
         Although there is strong evidence that
         <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">
          alprazolam
         </a>
         monotherapy is efficacious for treating unipolar depression, we rarely use this approach because of problems with abuse and dependency, particularly at higher doses (eg, &gt;2 mg per day).
        </p>
        <p>
         A systematic review of randomized trials that compared
         <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">
          alprazolam
         </a>
         with placebo in patients with unipolar major depression reported the following results [
         <a href="#rid41">
          41
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A meta-analysis of seven heterogeneous trials compared
         <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">
          alprazolam
         </a>
         with placebo in 771 patients who were treated for six weeks; the mean daily doses of alprazolam ranged from 2.1 to 3.7 mg and maximum daily doses ranged from 4.5 to 6 mg. Improvement of depressive symptoms was significantly greater with alprazolam than placebo.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A separate analysis of three homogeneous trials (312 patients) found that response (improvement from baseline on the depression rating scale ≥50 percent) occurred in more patients who received
         <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">
          alprazolam
         </a>
         than placebo (53 versus 22 percent).
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A third analysis of 17 trials (1636 patients) compared
         <a class="drug drug_general" data-topicid="8453" href="/z/d/drug information/8453.html" rel="external">
          alprazolam
         </a>
         with tricyclic antidepressants and found that improvement of symptoms was comparable; heterogeneity across studies was moderate to high. Alprazolam has not been directly compared with selective serotonin reuptake inhibitors (SSRIs).
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H30535230">
         <span class="h2">
          Nonbenzodiazepine hypnotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with unipolar major depression that includes insomnia, adding
         <a class="drug drug_general" data-topicid="8830" href="/z/d/drug information/8830.html" rel="external">
          eszopiclone
         </a>
         or
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          zolpidem
         </a>
         to an antidepressant is efficacious for treating insomnia, but it is not clear if these adjunctive drugs help resolve other core depressive symptoms. Evidence for the efficacy of these nonbenzodiazepine sedatives includes the following studies:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An eight-week randomized trial compared adjunctive
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          zolpidem
         </a>
         extended release (12.5 mg at bedtime) with placebo in 380 patients with unipolar major depression that included insomnia; all patients received
         <a class="drug drug_general" data-topicid="9046" href="/z/d/drug information/9046.html" rel="external">
          escitalopram
         </a>
         (10 mg per day) [
         <a href="#rid42">
          42
         </a>
         ]. Improvement of insomnia was greater in patients who received zolpidem than placebo; however, improvement of other depressive symptoms was comparable for both groups. Discontinuation of treatment due to adverse effects occurred in more patients who received adjunctive zolpidem than placebo (8 versus 4 percent). It is important to note that the United States Food and Drug Administration issued a Drug Safety Communication warning that zolpidem can impair driving and other activities that require alertness the next day [
         <a href="#rid43">
          43
         </a>
         ]. The recommended starting dose in females for extended release formulations is 6.25 mg, and for immediate release is 5 mg. The same doses are suggested for males as well.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         An eight-week randomized trial compared adjunctive
         <a class="drug drug_general" data-topicid="8830" href="/z/d/drug information/8830.html" rel="external">
          eszopiclone
         </a>
         (3 mg at bedtime) with placebo in 545 patients with unipolar major depression that included insomnia; all patients received
         <a class="drug drug_general" data-topicid="8465" href="/z/d/drug information/8465.html" rel="external">
          fluoxetine
         </a>
         20 to 40 mg per day [
         <a href="#rid6">
          6
         </a>
         ]. Insomnia improved more with eszopiclone than placebo, and improvement of other depressive symptoms was superior with eszopiclone. Discontinuation of treatment due to adverse effects was comparable in patients who received adjunctive eszopiclone or placebo (6 and 8 percent). Among the subgroup of patients with anxious depression (major depression that includes high levels of anxiety), insomnia and other depressive symptoms improved more with adjunctive eszopiclone than placebo [
         <a href="#rid44">
          44
         </a>
         ]. It is important to note that the United States Food and Drug Administration issued a Drug Safety Communication warning that 3 mg of eszopiclone can impair driving, memory, and coordination the next day [
         <a href="#rid45">
          45
         </a>
         ]. The recommended starting dose for males and females is 1 mg, which may be increased to 2 mg or 3 mg as needed.
        </p>
        <p>
        </p>
        <p>
         Abrupt discontinuation of the hypnotics in these two trials did not result in appreciable rebound insomnia, which is a significant advantage over benzodiazepines.
        </p>
        <p class="headingAnchor" id="H30535251">
         <span class="h2">
          Second-generation antipsychotics
         </span>
         <span class="headingEndMark">
          —
         </span>
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          Aripiprazole
         </a>
         ,
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         , and
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         and are each beneficial for anxious depression (major depression that includes high levels of anxiety). Evidence for the efficacy of these “major tranquilizers” includes the following studies [
         <a href="#rid46">
          46
         </a>
         ]:
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pooled analysis of two six-week randomized trials compared the efficacy of adjunctive
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          aripiprazole
         </a>
         (2 to 20 mg/day) with placebo in patients with unipolar major depression who were unresponsive to antidepressant monotherapy [
         <a href="#rid32">
          32
         </a>
         ]. In the subgroup of 435 patients with anxious depression, remission occurred in more patients who received aripiprazole than placebo (25 versus 16 percent). This was consistent with the finding that adjunctive aripiprazole was superior to placebo in nonanxious depression. Side effects associated with aripiprazole in patients with anxious depression included akathisia, fatigue insomnia, blurred vision, and constipation.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pooled analysis of two randomized trials that each lasted six weeks compared adjunctive
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         (2 or 3 mg/day) with placebo in patients with major depression who did not respond to open-label treatment with antidepressant monotherapy [
         <a href="#rid47">
          47
         </a>
         ]. In the subgroup of patients with anxious distress (n = 431), improvement of depression was greater with adjunctive brexpiprazole than placebo. This was consistent with the finding that adjunctive brexpiprazole was superior to placebo in nonanxious depression. Side effects associated with brexpiprazole in patients with anxious depression included akathisia, fatigue, restlessness, somnolence, and weight increase.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         A pooled analysis of two eight-week randomized trials compared the efficacy of
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         extended release monotherapy with placebo in patients with unipolar major depression [
         <a href="#rid33">
          33
         </a>
         ]. In the subgroup of 403 patients with anxious depression, response (improvement from baseline on the depression rating scale ≥50 percent) occurred in more patients who received quetiapine 150 mg or 300 mg/day than placebo (50 and 47 versus 32 percent). This was consistent with the finding that quetiapine was superior to placebo in nonanxious depression. Side effects of quetiapine include dry mouth, sedation, and weight gain.
        </p>
        <p>
        </p>
        <p>
         Additional information about adjunctive treatment with second-generation antipsychotics in patients with unipolar major depression who do not respond to antidepressant monotherapy is discussed separately. (See
         <a class="medical medical_review" href="/z/d/html/14688.html" rel="external">
          "Unipolar depression in adults: Treatment with second-generation antipsychotics"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H172922575">
         <span class="h2">
          Pindolol
         </span>
         <span class="headingEndMark">
          —
         </span>
         For patients with unipolar major depression, adding the beta blocker
         <a class="drug drug_general" data-topicid="9774" href="/z/d/drug information/9774.html" rel="external">
          pindolol
         </a>
         (eg, 5 mg three times per day) to a selective serotonin reuptake inhibitor (SSRI) can improve depressive symptoms and may accelerate clinical response via blockade of the 5-HT1A autoreceptor. A meta-analysis of 12 randomized trials compared pindolol plus an SSRI with placebo plus an SSRI in 889 patients with unipolar major depression and no history of treatment resistance. Response (improvement from baseline on the depression rating scale ≥50 percent) at two weeks occurred in more patients who received adjunctive pindolol than placebo (37 versus 21 percent); however, heterogeneity across trials was high [
         <a href="#rid48">
          48
         </a>
         ]. In a second analysis, response at four to six weeks occurred in more patients who received adjunctive pindolol than placebo (74 versus 67 percent), and there was little to no heterogeneity.
        </p>
        <p class="headingAnchor" id="H172922236">
         <span class="h2">
          Buspirone
         </span>
         <span class="headingEndMark">
          —
         </span>
         Augmentation with
         <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">
          buspirone
         </a>
         does not appear to help patients with anxious depression (major depression that includes high levels of anxiety). The effectiveness of buspirone was evaluated in the Sequenced Treatment Alternatives to Relieve Depression (STAR*D) study, which compared buspirone (mean dose 41 mg per day) plus
         <a class="drug drug_general" data-topicid="8874" href="/z/d/drug information/8874.html" rel="external">
          citalopram
         </a>
         with
         <a class="drug drug_general" data-topicid="9171" href="/z/d/drug information/9171.html" rel="external">
          bupropion
         </a>
         sustained release (mean dose 268 mg per day) plus citalopram in 565 patients with unipolar major depression who were initially unresponsive to citalopram monotherapy [
         <a href="#rid49">
          49
         </a>
         ]. Treatment was randomly assigned and administered on an open label basis, assessment of outcome was blinded, and concomitant use of
         <a class="drug drug_general" data-topicid="10013" href="/z/d/drug information/10013.html" rel="external">
          trazodone
         </a>
         and benzodiazepines was permitted. Among patients with anxious depression who received adjunctive buspirone, remission occurred in only 9 percent, compared to 39 percent of patients with nonanxious depression [
         <a href="#rid3">
          3
         </a>
         ].
        </p>
        <p class="headingAnchor" id="H90524902">
         <span class="h2">
          Other agents
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Doxepin
         </strong>
         – Randomized trials have demonstrated that the tricyclic antidepressant
         <a class="drug drug_general" data-topicid="9390" href="/z/d/drug information/9390.html" rel="external">
          doxepin
         </a>
         (3 or 6 mg at bedtime) is efficacious for insomnia in patients who are not depressed (see
         <a class="medical medical_review" href="/z/d/html/97868.html" rel="external">
          "Pharmacotherapy for insomnia in adults", section on 'Antidepressants'
         </a>
         ). The drug may also be useful for insomnia associated with depression, but this has not been studied in a randomized trial.
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <strong>
          Riluzole
         </strong>
         – A prospective observational study of 10 patients with unipolar major depression and anxiety found that augmentation of the antidepressant regimen with
         <a class="drug drug_general" data-topicid="9865" href="/z/d/drug information/9865.html" rel="external">
          riluzole
         </a>
         (used to treat amyotrophic lateral sclerosis) reduced symptoms of depression and anxiety [
         <a href="#rid50">
          50
         </a>
         ].
        </p>
        <p>
        </p>
        <p class="headingAnchor" id="H477341499">
         <span class="h1">
          SOCIETY GUIDELINE LINKS
         </span>
         <span class="headingEndMark">
          —
         </span>
         Links to society and government-sponsored guidelines from selected countries and regions around the world are provided separately. (See
         <a class="medical medical_society_guidelines" href="/z/d/html/114814.html" rel="external">
          "Society guideline links: Benzodiazepine use disorder and withdrawal"
         </a>
         .)
        </p>
        <p class="headingAnchor" id="H30535294">
         <span class="h1">
          SUMMARY
         </span>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Unipolar major depression often includes symptoms of anxiety such as worrying or rumination, and is referred to as anxious depression. Anxiety symptoms that are part of a depressive syndrome are distinguished from anxiety disorders that are comorbid with depressive disorders. (See
         <a class="local">
          'Anxious depression'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14623.html" rel="external">
          "Comorbid anxiety and depression in adults: Epidemiology, clinical manifestations, and diagnosis"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Acute treatment of unipolar major depression with antidepressants is less effective in patients with higher levels of baseline anxiety than patients with lower levels. However, adjunctive anxiolytics can improve outcomes in anxious depression. Indications for augmenting antidepressants with anxiolytics to treat unipolar major depression include symptoms of anxiety, moderate to severe insomnia, psychomotor agitation, excessive activation induced by antidepressants, the need to accelerate improvement in patients with moderate to severe depression, and treatment resistant depression. (See
         <a class="local">
          'Anxious depression'
         </a>
         above and
         <a class="local">
          'Indications'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14685.html" rel="external">
          "Unipolar depression in adults: Choosing treatment for resistant depression"
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Contraindications to augmenting antidepressants with anxiolytics (especially benzodiazepines) to treat depression include several comorbidities, such as chronic posttraumatic stress disorder, severe antisocial or borderline personality disorder, moderate to severe substance use disorders antedating onset of the depressive syndrome, mild cognitive impairment or dementia, and general medical conditions such as severe myopathic disorders and chronic respiratory disease. (See
         <a class="local">
          'Contraindications'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Depressive symptoms can be assessed with the self-report Patient Health Questionnaire - 9 Item (PHQ-9)  (
         <a class="graphic graphic_table graphicRef59307" href="/z/d/graphic/59307.html" rel="external">
          table 2
         </a>
         ), and anxiety symptoms with the self-report scale for generalized anxiety disorder (GAD-7). A reasonable alternative is to use self-report visual analog scales. (See
         <a class="local">
          'Patient assessment'
         </a>
         above and
         <a class="medical medical_review" href="/z/d/html/14860.html" rel="external">
          "Using scales to monitor symptoms and treat depression (measurement based care)", section on 'Patient Health Questionnaire - Nine Item'
         </a>
         .)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         In using an adjunctive anxiolytic to treat severe unipolar major depression that includes anxiety and/or insomnia, we typically start the anxiolytic at the same time as the antidepressant. For mild to moderate depression, we generally use a stepped care approach, in which the antidepressant is titrated up and administered for a sufficient period to evaluate its efficacy as monotherapy; if anxiety and/or insomnia persist, we then add the anxiolytic. (See
         <a class="local">
          'When to start the anxiolytic'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         We generally co-administer the anxiolytic and the antidepressant for four to six weeks, and then taper the anxiolytic for two to four weeks prior to discontinuation. However, longer taper schedules may be necessary for benzodiazepines. (See
         <a class="local">
          'Duration of treatment'
         </a>
         above and
         <a class="local">
          'Benzodiazepines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with unipolar major depression, prescribing a benzodiazepine (eg,
         <a class="drug drug_general" data-topicid="9284" href="/z/d/drug information/9284.html" rel="external">
          clonazepam
         </a>
         0.5 to 2 mg/day at bedtime or divided in two daily doses) plus an antidepressant can improve symptoms of anxiety and depression, and also improve treatment adherence. However, the potential harms of adding a benzodiazepine include tolerance (diminished effect over time), physiologic dependence, sedation, amnestic effects, impaired psychomotor speed, and increased accidents. (See
         <a class="local">
          'Benzodiazepines'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For unipolar major depression that includes insomnia, adding
         <a class="drug drug_general" data-topicid="8830" href="/z/d/drug information/8830.html" rel="external">
          eszopiclone
         </a>
         (3 mg at bedtime) or
         <a class="drug drug_general" data-topicid="10057" href="/z/d/drug information/10057.html" rel="external">
          zolpidem
         </a>
         extended release (females 6.25 mg/males 6.25 or 12.5 mg at bedtime) to an antidepressant is efficacious for treating insomnia. However, it is not clear if these adjunctive drugs help resolve other core depressive symptoms. Abrupt discontinuation of these nonbenzodiazepine hypnotics does not result in appreciable rebound insomnia, which is a significant advantage over benzodiazepines. (See
         <a class="local">
          'Nonbenzodiazepine hypnotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         <a class="drug drug_general" data-topicid="8786" href="/z/d/drug information/8786.html" rel="external">
          Aripiprazole
         </a>
         (2 to 20 mg/day),
         <a class="drug drug_general" data-topicid="102739" href="/z/d/drug information/102739.html" rel="external">
          brexpiprazole
         </a>
         (2 or 3 mg/day), and
         <a class="drug drug_general" data-topicid="9570" href="/z/d/drug information/9570.html" rel="external">
          quetiapine
         </a>
         (150 mg or 300 mg/day)are each beneficial for anxious depression (major depression that includes high levels of anxiety). (See
         <a class="local">
          'Second-generation antipsychotics'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         For patients with unipolar major depression who are treated with an antidepressant, adding
         <a class="drug drug_general" data-topicid="9774" href="/z/d/drug information/9774.html" rel="external">
          pindolol
         </a>
         (eg, 5 mg three times/day) can accelerate or improve response to the antidepressant. (See
         <a class="local">
          'Pindolol'
         </a>
         above.)
        </p>
        <p>
        </p>
        <p class="bulletIndent1">
         <span class="glyph">
          ●
         </span>
         Augmentation with
         <a class="drug drug_general" data-topicid="9172" href="/z/d/drug information/9172.html" rel="external">
          buspirone
         </a>
         does not appear to help patients with anxious depression. (See
         <a class="local">
          'Buspirone'
         </a>
         above.)
        </p>
        <p>
        </p>
       </div>
       <div class="headingAnchor" id="references">
        <ol id="reference">
         <li>
          <a class="nounderline abstract_t">
           Köhler S, Unger T, Hoffmann S, et al. Acute and long-term treatment outcome in depressed inpatients with vs. without anxious features: results of a one-year follow-up study. J Affect Disord 2013; 150:1055.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Wu Z, Chen J, Yuan C, et al. Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study. J Affect Disord 2013; 150:834.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava M, Rush AJ, Alpert JE, et al. Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report. Am J Psychiatry 2008; 165:342.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furukawa TA, Streiner DL, Young LT. Antidepressant plus benzodiazepine for major depression. Cochrane Database Syst Rev 2001; :CD001026.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Bushnell GA, Stürmer T, Gaynes BN, et al. Simultaneous Antidepressant and Benzodiazepine New Use and Subsequent Long-term Benzodiazepine Use in Adults With Depression, United States, 2001-2014. JAMA Psychiatry 2017; 74:747.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava M, McCall WV, Krystal A, et al. Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder. Biol Psychiatry 2006; 59:1052.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Ionescu DF, Niciu MJ, Henter ID, Zarate CA. Defining anxious depression: a review of the literature. CNS Spectr 2013; 18:252.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Katz C, Yaseen ZS, Mojtabai R, et al. Panic as an independent risk factor for suicide attempt in depressive illness: findings from the National Epidemiological Survey on Alcohol and Related Conditions (NESARC). J Clin Psychiatry 2011; 72:1628.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Richey SM, Krystal AD. Pharmacological advances in the treatment of insomnia. Curr Pharm Des 2011; 17:1471.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Allen MH, Currier GW, Hughes DH, et al. The Expert Consensus Guideline Series. Treatment of behavioral emergencies. Postgrad Med 2001; :1.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sinclair LI, Christmas DM, Hood SD, et al. Antidepressant-induced jitteriness/anxiety syndrome: systematic review. Br J Psychiatry 2009; 194:483.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Papakostas GI, Clain A, Ameral VE, et al. Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study. Int Clin Psychopharmacol 2010; 25:17.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Jeffreys M, Capehart B, Friedman MJ. Pharmacotherapy for posttraumatic stress disorder: review with clinical applications. J Rehabil Res Dev 2012; 49:703.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Pascual JC, Martín-Blanco A, Soler J, et al. A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines. Int Clin Psychopharmacol 2010; 25:349.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Manthey L, Lohbeck M, Giltay EJ, et al. Correlates of benzodiazepine dependence in the Netherlands Study of Depression and Anxiety. Addiction 2012; 107:2173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Tannenbaum C, Paquette A, Hilmer S, et al. A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs. Drugs Aging 2012; 29:639.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Haroutiunian S, Lecht S, Zur AA, et al. The challenge of pain management in patients with myasthenia gravis. J Pain Palliat Care Pharmacother 2009; 23:242.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           George CF, Bayliff CD. Management of insomnia in patients with chronic obstructive pulmonary disease. Drugs 2003; 63:379.
          </a>
         </li>
         <li class="breakAll">
          Freudenreich O, Nejad SH, Francis A, Fricchione GL. Psychosis, mania, and catatonia. In: Textbook of Psychosomatic Medicine: Psychiatric Care of the Medically Ill, Second Edition, Levenson JL (Ed), American Psychiatric Publishing, Washington, DC 2011. p.219.
         </li>
         <li class="breakAll">
          Rothschild AJ. Clinical Manual for Diagnosis and Treatment of Psychotic Depression, American Psychiatric Publishing, Inc., Washington, DC 2009.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Work Group on Psychiatric Evaluation, American Psychiatric Association Steering Committee on Practice Guidlines. Psychiatric evaluation of adults. Second edition. American Psychiatric Association. Am J Psychiatry 2006; 163:3.
          </a>
         </li>
         <li class="breakAll">
          American Psychiatric Association Practice Guideline for the Psychiatric Evaluation of Adults, Second Edition, 2006. http://www.psych.org/MainMenu/PsychiatricPractice/PracticeGuidelines_1.aspx (Accessed on July 18, 2011).
         </li>
         <li class="breakAll">
          American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition (DSM-5), American Psychiatric Association, 2013.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kroenke K, Spitzer RL, Williams JB. The PHQ-9: validity of a brief depression severity measure. J Gen Intern Med 2001; 16:606.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Kroenke K, Spitzer RL, Williams JB. The Patient Health Questionnaire-2: validity of a two-item depression screener. Med Care 2003; 41:1284.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Spitzer RL, Kroenke K, Williams JB, Löwe B. A brief measure for assessing generalized anxiety disorder: the GAD-7. Arch Intern Med 2006; 166:1092.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Steer RA, Ranieri WF, Beck AT, Clark DA. Further evidence for the validity of the Beck Anxiety Inventory with psychiatric outpatients. J Anxiety Disord 1993; 7:195.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Muntingh AD, van der Feltz-Cornelis CM, van Marwijk HW, et al. Is the Beck Anxiety Inventory a good tool to assess the severity of anxiety? A primary care study in the Netherlands Study of Depression and Anxiety (NESDA). BMC Fam Pract 2011; 12:66.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           HAMILTON M. The assessment of anxiety states by rating. Br J Med Psychol 1959; 32:50.
          </a>
         </li>
         <li class="breakAll">
          Shear MK, Brown C, Clark DB. Anxiety disorders measures. In: Handbook of Psychiatric Measures, Second Edition, Rush Jr AJ, First MB, Blacker D (Eds), American Psychiatric Publishing, Inc., Washington, DC 2008. p.529.
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava GA, Ruini C, Rafanelli C. Sequential treatment of mood and anxiety disorders. J Clin Psychiatry 2005; 66:1392.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trivedi MH, Thase ME, Fava M, et al. Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features. J Clin Psychiatry 2008; 69:1928.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Thase ME, Demyttenaere K, Earley WR, et al. Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression. Depress Anxiety 2012; 29:574.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith WT, Londborg PD, Glaudin V, Painter JR. Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study. Am J Psychiatry 1998; 155:1339.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Smith WT, Londborg PD, Glaudin V, et al. Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression? J Affect Disord 2002; 70:251.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Furukawa TA, Streiner DL, Young LT. Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study. J Affect Disord 2001; 65:173.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Chang CM, Wu EC, Chen CY, et al. Psychotropic drugs and risk of motor vehicle accidents: a population-based case-control study. Br J Clin Pharmacol 2013; 75:1125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dassanayake T, Michie P, Carter G, Jones A. Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence. Drug Saf 2011; 34:125.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Westra HA, Stewart SH, Conrad BE. Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia. J Anxiety Disord 2002; 16:233.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Feet PO, Larsen S, Lillevold PE, Robak OH. Withdrawal reactions to diazepam in combined imipramine/diazepam treatment of primary nonagitated depressed outpatients. Acta Psychiatr Scand 1988; 78:341.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           van Marwijk H, Allick G, Wegman F, et al. Alprazolam for depression. Cochrane Database Syst Rev 2012; :CD007139.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava M, Asnis GM, Shrivastava RK, et al. Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial. J Clin Psychiatry 2011; 72:914.
          </a>
         </li>
         <li class="breakAll">
          FDA Drug Safety Communication: Risk of next-morning impairment after use of insomnia drugs; FDA requires lower recommended doses for certain drugs containing zolpidem (Ambien, Ambien CR, Edluar, and Zolpimist). http://www.fda.gov/Drugs/DrugSafety/ucm334033.htm (Accessed on June 26, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Fava M, Schaefer K, Huang H, et al. A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression. J Clin Psychiatry 2011; 72:473.
          </a>
         </li>
         <li class="breakAll">
          FDA Drug Safety Communication: FDA warns of next-day impairment with sleep aid Lunesta (eszopiclone) and lowers recommended dose. http://www.fda.gov/Drugs/DrugSafety/ucm397260.htm (Accessed on June 26, 2014).
         </li>
         <li>
          <a class="nounderline abstract_t">
           Dannlowski U, Baune BT, Böckermann I, et al. Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates. Hum Psychopharmacol 2008; 23:587.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           McIntyre RS, Weiller E, Zhang P, Weiss C. Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials. J Affect Disord 2016; 201:116.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Portella MJ, de Diego-Adeliño J, Ballesteros J, et al. Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression. J Clin Psychiatry 2011; 72:962.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Trivedi MH, Fava M, Wisniewski SR, et al. Medication augmentation after the failure of SSRIs for depression. N Engl J Med 2006; 354:1243.
          </a>
         </li>
         <li>
          <a class="nounderline abstract_t">
           Sanacora G, Kendell SF, Levin Y, et al. Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms. Biol Psychiatry 2007; 61:822.
          </a>
         </li>
        </ol>
       </div>
       <div id="topicVersionRevision">
        Topic 14670 Version 20.0
       </div>
      </div>
      <div class="row">
       <div class="col-12">
        <h4 style="text-align: center;padding: 20px;color: cadetblue;">
         References
        </h4>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23764380" id="rid0" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          1 : Acute and long-term treatment outcome in depressed inpatients with vs. without anxious features: results of a one-year follow-up study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23570952" id="rid1" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          2 : Difference in remission in a Chinese population with anxious versus nonanxious treatment-resistant depression: a report of OPERATION study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18172020" id="rid2" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          3 : Difference in treatment outcome in outpatients with anxious versus nonanxious depression: a STAR*D report.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11405972" id="rid3" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          4 : Antidepressant plus benzodiazepine for major depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/28593281" id="rid4" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          5 : Simultaneous Antidepressant and Benzodiazepine New Use and Subsequent Long-term Benzodiazepine Use in Adults With Depression, United States, 2001-2014.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16581036" id="rid5" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          6 : Eszopiclone co-administered with fluoxetine in patients with insomnia coexisting with major depressive disorder.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23507190" id="rid6" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          7 : Defining anxious depression: a review of the literature.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21457675" id="rid7" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          8 : Panic as an independent risk factor for suicide attempt in depressive illness: findings from the National Epidemiological Survey on Alcohol and Related Conditions (NESARC).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21476952" id="rid8" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          9 : Pharmacological advances in the treatment of insomnia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11500996" id="rid9" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          10 : The Expert Consensus Guideline Series. Treatment of behavioral emergencies.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19478285" id="rid10" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          11 : Antidepressant-induced jitteriness/anxiety syndrome: systematic review.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19898245" id="rid11" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          12 : Fluoxetine-clonazepam cotherapy for anxious depression: an exploratory, post-hoc analysis of a randomized, double blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/23015581" id="rid12" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          13 : Pharmacotherapy for posttraumatic stress disorder: review with clinical applications.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/20838221" id="rid13" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          14 : A naturalistic study of changes in pharmacological prescription for borderline personality disorder in clinical practice: from APA to NICE guidelines.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22703562" id="rid14" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          15 : Correlates of benzodiazepine dependence in the Netherlands Study of Depression and Anxiety.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22812538" id="rid15" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          16 : A systematic review of amnestic and non-amnestic mild cognitive impairment induced by anticholinergic, antihistamine, GABAergic and opioid drugs.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19670021" id="rid16" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          17 : The challenge of pain management in patients with myasthenia gravis.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12558460" id="rid17" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          18 : Management of insomnia in patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12558460" id="rid18" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          19 : Management of insomnia in patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12558460" id="rid19" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          20 : Management of insomnia in patients with chronic obstructive pulmonary disease.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16866240" id="rid20" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          21 : Psychiatric evaluation of adults. Second edition. American Psychiatric Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16866240" id="rid21" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          22 : Psychiatric evaluation of adults. Second edition. American Psychiatric Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16866240" id="rid22" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          23 : Psychiatric evaluation of adults. Second edition. American Psychiatric Association.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11556941" id="rid23" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          24 : The PHQ-9: validity of a brief depression severity measure.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/14583691" id="rid24" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          25 : The Patient Health Questionnaire-2: validity of a two-item depression screener.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16717171" id="rid25" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          26 : A brief measure for assessing generalized anxiety disorder: the GAD-7.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/" id="rid26" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          27 : Further evidence for the validity of the Beck Anxiety Inventory with psychiatric outpatients
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21726443" id="rid27" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          28 : Is the Beck Anxiety Inventory a good tool to assess the severity of anxiety? A primary care study in the Netherlands Study of Depression and Anxiety (NESDA).
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13638508" id="rid28" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          29 : The assessment of anxiety states by rating.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/13638508" id="rid29" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          30 : The assessment of anxiety states by rating.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16420076" id="rid30" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          31 : Sequential treatment of mood and anxiety disorders.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/19192475" id="rid31" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          32 : Adjunctive aripiprazole in major depressive disorder: analysis of efficacy and safety in patients with anxious and atypical features.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22753280" id="rid32" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          33 : Extended release quetiapine fumarate in major depressive disorder: analysis in patients with anxious depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/9766764" id="rid33" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          34 : Short-term augmentation of fluoxetine with clonazepam in the treatment of depression: a double-blind study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12128237" id="rid34" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          35 : Is extended clonazepam cotherapy of fluoxetine effective for outpatients with major depression?
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/11356241" id="rid35" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          36 : Is antidepressant-benzodiazepine combination therapy clinically more useful? A meta-analytic study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22971090" id="rid36" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          37 : Psychotropic drugs and risk of motor vehicle accidents: a population-based case-control study.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21247221" id="rid37" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          38 : Effects of benzodiazepines, antidepressants and opioids on driving: a systematic review and meta-analysis of epidemiological and experimental evidence.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/12214810" id="rid38" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          39 : Naturalistic manner of benzodiazepine use and cognitive behavioral therapy outcome in panic disorder with agoraphobia.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/3057815" id="rid39" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          40 : Withdrawal reactions to diazepam in combined imipramine/diazepam treatment of primary nonagitated depressed outpatients.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/22786504" id="rid40" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          41 : Alprazolam for depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208597" id="rid41" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          42 : Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208597" id="rid42" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          43 : Improved insomnia symptoms and sleep-related next-day functioning in patients with comorbid major depressive disorder and insomnia following concomitant zolpidem extended-release 12.5 mg and escitalopram treatment: a randomized controlled trial.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208574" id="rid43" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          44 : A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21208574" id="rid44" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          45 : A post hoc analysis of the effect of nightly administration of eszopiclone and a selective serotonin reuptake inhibitor in patients with insomnia and anxious depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/18663773" id="rid45" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          46 : Adjunctive antidepressant treatment with quetiapine in agitated depression: positive effects on symptom reduction, psychopathology and remission rates.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/27208498" id="rid46" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          47 : Brexpiprazole as adjunctive treatment of major depressive disorder with anxious distress: Results from a post-hoc analysis of two randomised controlled trials.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/21034693" id="rid47" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          48 : Can we really accelerate and enhance the selective serotonin reuptake inhibitor antidepressant effect? A randomized clinical trial and a meta-analysis of pindolol in nonresistant depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/16554526" id="rid48" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          49 : Medication augmentation after the failure of SSRIs for depression.
         </p>
        </a>
       </div>
       <div class="col-12" style="text-align: left;direction: ltr">
        <a href="https://pubmed.ncbi.nlm.nih.gov/17141740" id="rid49" target="_blank">
         <p class="btn-info round" style='width: 100%;margin-bottom: 5px !important;padding: 10px;border-radius: 12px;;font-family: Arial, "Helvetica Neue", Helvetica, sans-serif;'>
          50 : Preliminary evidence of riluzole efficacy in antidepressant-treated patients with residual depressive symptoms.
         </p>
        </a>
       </div>
      </div>
     </div>
    </div>
   </section>
  </section>
  <!-- End Main Menu Area -->
  <!-- Start Search Popup Area -->
  <!-- End Footer Area -->
  <!-- Back to top -->
  <a class="scrolltop" href="#top">
   <i class="icofont-hand-drawn-up">
   </i>
  </a>
  <!-- End Back to top -->
  <!-- jQuery Min JS -->
  <!-- Prpper JS -->
  <!-- Bootstrap Min JS -->
  <!-- Classy Nav Min Js -->
  <!-- Owl Carousel Min Js -->
  <!-- Magnific Popup JS -->
  <!-- CounterUp JS -->
  <!-- Waypoints JS -->
  <!-- Form Validator Min JS -->
  <!-- Contact Form Min JS -->
  <!-- Main JS -->
  <!-- Global site tag (gtag.js) - Google Analytics -->
 </body>
</html>
